MAY 2 = 2000 TH. 18 . T. 18 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Anticipated Classification Prior Application Attorney's of this Application. Exam r Mary M. Schmidt. Docket No.: Enz-53(D4)(FWC) Group Art Unit: Not Yet Known Class _ ___ Subclass Prior Group Art Unit: 1635 FILED BY FIRST CLASS MAIL Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231 BOX FWC (if under §1.62) Sir: This is a request for filing a X CONTINUATION DIVISIONAL CONTINUATION-IN-PART application under __ 37 CFR §1.60 __X 37 CFR §1.62, of pending prior application Serial No. 08/978,635 filed on November 25, 1997 Elazar Rabbani et al. Inventor(s) PROCESS FOR SELECTIVE EXPRESSION OF NUCLEIC ACID for: CONSTRUCTS (As Previously Amended) Title of Invention Enclosed is a copy of the prior application, as originally filed and an affidavit or declaration verifying it as a true copy. A copy of the verified statement under 37 CFR §1.9 and §1.27 2. establishing small entity status in the prior application is enclosed. Small entity status is still applicable. The filing fee is calculated as follows: 3. Χ CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT FEE **RATE** Other Small Other Small Number Number Entity Entity Entity Extra Entity Filed \$ 690-0 \$ 9 \$ 18 \$ 0 7 Х Total Claims \$ 0 \$ 78 \$ ---Independent 0 \$ --Claims \$ ---Multiple Dependent _Yes ___ No \$ Claims Presented \$130 \$260 If the difference in Col. 1 is less than zero, enter "0" in Col.2 **BASIC** \$690 FEE \$345 .5 31/2000 S#EFERRA 00000007 051135 - 08978635 TOTAL \$ 0 FEE \$345 345.00 CH 1 77:231 The Commissioner is hereby authorized to charge payment of the Χ.___ filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No. 05-1135. A duplicate copy of this sheet is enclosed

Any additional filing fees required under 37 CFR §1.16.

Any patent application processing fees under 37 CFR §1.17

denomined this date with the U.S. Postal Factors we first class mall addressed to commissioner of patents and Trademarks, in schington, P.C. 19891

MAY 23 200

MAY 23 200

Date

I horeby certify that this paner is being

Attorney's Docket No. Enz-53(D4)(FWC)

Х

Χ

Elazar Rabbanı et al Senal No Not Yet Assigned

Filed Herewith

Page 2 (Request for a Continuation Application Under 37 C F R. §1.62 May 23, 2000)

5.	X	The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. <u>05-1135</u> . A duplicate copy of this sheet is enclosed.		
		X Any patent application processing fees under 37 CFR §1.17. The issue fee set in 37 CFR §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR §1.311(b). Any filing fees under 37 CFR §1.16 for presentation of extra claims.		
6.		A check in the amount of \$ is enclosed.		
7.		Cancel claims		
8.	_X	Amend the specification by inserting before the first line of the sentence: This is a <u>X</u> continuation, <u>divisional</u> , <u>divisional</u> , <u>continuation-in-part</u> , of application Serial No. 08/978,635, filed on November 25, 1997		
9.		Transfer the drawings from the prior application.		
10.		Informal formal drawings are enclosed.		
11.		Abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.		
12. Priority of application		Priority of application Serial No filed on		
		is claimed under 35 U.S.C. §119. The certified copy of the priority application has been filed in prior application Serial No		
13.		The prior application is assigned of record to Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022. [A copy of the originally submitted Assignment and the Notice of Recordation are enclosed herewith.]		
14.		A preliminary amendment is enclosed.		
15.	X	The power of attorney in the prior application is to: Ronald C. Fedus, Reg. No. 32,567.		
		(a) X The power appears in the original papers in the prior application.		
		(b) Since the power does not appear in the original papers. a copy of the power in the prior application is enclosed		
		(c) A copy of a new substitute power of attorney is enclosed.		

Serial No. Not Yet	Assigned			
Filed, Herewith				
Page 3 (Request for a Continuation Application Under 37 C.F.R. §1.62 - May 23, 2000)				
	(d) <u>X</u>	Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)		
		Ronald C. Fedus, Esq. Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue (9th Floor) New York, New York 10022		
16.		fy that the attached papers are a true copy of prior serial No		
are true and that all and further that the statements and the Section 1001 of Title	statements n ese statement like so made e 18 of the Ur	r that all statements made herein of his own knowledge nade on information and belief are believed to be true; s were made with the knowledge that willful false are punishable by fine or imprisonment, or both, under nited States Code and that such willful false statements application or any patent issuing thereon. Ronald C. Fedus Registration No. 32, 567 Attorney for Applicants Inventor(s) Assignee of Complete Interest X Attorney or Agent of Record Filed under 37 CFR §1.34(a)		

Address of Signator: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue (9th Floor) New York, New York 10022

Elazar Rabbanı et al

laword/usprosecution/enz53(D4) 052300